Kate Watkins is an Analyst at CBPartners.
Connect with Kate Watkins
CBPartners' Digital Therapeutics & Health Technology Expertise Team summarizes the approval of the first AI-based software designed to identify areas of concern on a prostate biopsy image.
Verily recently announced its first major acquisition, a software platform known as SignalPath. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform.
KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health concerns is a step towards modernizing healthcare and represents a very structured approach to real-world data generation.
